Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's What Happened

Key Points

• Ascentage Pharma Group International shares experienced a significant increase, gapping up from a previous close of $37.60 to an opening price of $41.50, representing a 10.4% rise.
• A hedge fund, Chevy Chase Trust Holdings LLC, has acquired a new stake in the company, purchasing 5,753 shares valued at approximately $227,000 during the second quarter.
• Ascentage Pharma is a clinical-stage biotechnology company focused on developing therapies for cancers, hepatitis B, and age-related diseases, established in May 2009 in Suzhou, China.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - ) gapped up prior to trading on Tuesday . The stock had previously closed at $37.60, but opened at $41.50. Ascentage Pharma Group International shares last traded at $41.21, with a volume of 13,722 shares changing hands.

Ascentage Pharma Group International Stock Up 10.4%

The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24. The stock's fifty day moving average price is $35.68.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Chevy Chase Trust Holdings LLC acquired a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,753 shares of the company's stock, valued at approximately $227,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.